The setup for Q4. HealthEquity will report its fiscal fourth-quarter 2026 results on March 17, after markets close, with the earnings call scheduled for 4:30 PM ET. Wall Street expects EPS of $0.90, up 30.1% from the $0.69 reported in the year-ago quarter. Revenue consensus stands at $332.8 million, representing 6.7% growth from last year’s $311.8 million.
What matters most. For this health savings account administrator, investors will focus on account growth momentum and custodial asset trends as employers finalize benefits enrollment for the new plan year. The company’s ability to convert new employer clients and expand wallet share with existing accounts will determine whether the 6.7% revenue growth trajectory can accelerate. With the stock trading 32.6% below its 52-week high of $116.65, the market is pricing in execution risk despite the company’s strong profitability track record.
A consistent beat pattern. HealthEquity has delivered above-consensus results in three of the last four quarters. Earnings exceeded estimates in each of the trailing three quarters.
Estimates holding steady. The consensus EPS estimate of $0.90 has remained remarkably stable, drifting slightly lower from $0.8985 over the past 30 days. Revision activity has been balanced, with one upward and one downward revision in the past week. For the full fiscal year 2026, analysts project EPS of $3.95, up 26.8% from fiscal 2025’s $3.12.
Wall Street remains bullish. The analyst community maintains a strongly positive stance, with 14 of 16 analysts rating the stock Buy or Strong Buy. Just one analyst holds a Hold rating, and one rates it Sell. This 87.5% buy-side consensus reflects confidence in the company’s position as a leading HSA platform provider in the growing consumer-directed healthcare market.
Recent price target cuts. Despite the bullish ratings, analysts have trimmed price targets in recent weeks. Barclays maintained its Overweight rating on February 18 but lowered its target to $110 from $118. BTIG followed suit the day prior, keeping its Buy rating while cutting the target to $110 from $130. The most notable move came from Goldman Sachs, which downgraded the stock to Sell from Neutral on January 9 with an $89 price target.
The key question. With the stock down sharply from its highs and trading below the most pessimistic Wall Street price target, the earnings report will test whether the company’s consistent execution can reignite investor confidence. The market is demanding proof that account growth can reaccelerate and that the HSA platform business model remains resilient despite increased competition in the benefits administration space.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.